The proteasome, a multiprotease complex, is clinically validated as an anticancer target by the FDA approval of bortezomib and carfilzomib for the treatment of multiple myeloma. The emergence of resistance to proteasome inhibitors however remains a major clinical challenge. Recently, distinct types of proteasomes termed ‘intermediate proteasomes’, which contain unconventional mixtures of catalytic subunits, have been implicated with drug resistance of tumor cells. In elucidating the role of intermediate proteasomes in drug resistance, a crucial step is to unequivocally determine the subunit composition of intermediate proteasomes in cells. With this in mind, the goal of the studies reported in this dissertation is to develop novel chemical ...
This thesis describes the design, synthesis and application of chemical tools for the activity-based...
The ubiquitin proteasome pathway is one of the major protein degradation pathways in the cell. This ...
This thesis describes the design and development of subunit‐selective inhibitors of particular c...
The proteasome, a multiprotease complex, is clinically validated as an anticancer target by the FDA ...
Proteasome inhibitors bortezomib and carfilzomib are FDA-approved anticancer agents that have contri...
STEP Category: Undergraduate ResearchThe proteasome is a critical component of the ubiquitin-proteas...
Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and ixazomib, have contrib...
The 26S proteasome is a 2.4 MDa multifunctional ATP-dependent proteolytic complex, which degrades th...
Proteasomes are multi-protein, multi-catalytic complexes responsible for the degradation of 80-90%...
AbstractBackground: The proteasome is a large multicatalytic protease complex (700 kDa) involved in ...
The proteasome is an essential evolutionary conserved protease involved in many regulatory systems. ...
Abstract: Proteasome inhibition is a therapeutic concept of current interest in anticancer research....
Proteasomes play an important role in protein degradation and regulation of many cellular pathways b...
20S proteasomes are large, multicatalytic N- terminal threonine proteases which are tasked with main...
The ubiquitin-proteasome system plays an important role in cellular homeostasis and also has a criti...
This thesis describes the design, synthesis and application of chemical tools for the activity-based...
The ubiquitin proteasome pathway is one of the major protein degradation pathways in the cell. This ...
This thesis describes the design and development of subunit‐selective inhibitors of particular c...
The proteasome, a multiprotease complex, is clinically validated as an anticancer target by the FDA ...
Proteasome inhibitors bortezomib and carfilzomib are FDA-approved anticancer agents that have contri...
STEP Category: Undergraduate ResearchThe proteasome is a critical component of the ubiquitin-proteas...
Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and ixazomib, have contrib...
The 26S proteasome is a 2.4 MDa multifunctional ATP-dependent proteolytic complex, which degrades th...
Proteasomes are multi-protein, multi-catalytic complexes responsible for the degradation of 80-90%...
AbstractBackground: The proteasome is a large multicatalytic protease complex (700 kDa) involved in ...
The proteasome is an essential evolutionary conserved protease involved in many regulatory systems. ...
Abstract: Proteasome inhibition is a therapeutic concept of current interest in anticancer research....
Proteasomes play an important role in protein degradation and regulation of many cellular pathways b...
20S proteasomes are large, multicatalytic N- terminal threonine proteases which are tasked with main...
The ubiquitin-proteasome system plays an important role in cellular homeostasis and also has a criti...
This thesis describes the design, synthesis and application of chemical tools for the activity-based...
The ubiquitin proteasome pathway is one of the major protein degradation pathways in the cell. This ...
This thesis describes the design and development of subunit‐selective inhibitors of particular c...